Meiji Holdings (2269) FY2027 Q1 Earnings Report

Quick View

Executive Summary

In addition to higher revenue and earnings, profit growth significantly outpaced revenue growth, resulting in improved profitability. Revenue was ¥2,894.0B (+5.8% YoY), Operating Income was ¥226.7B (+27.7%), Ordinary Income was ¥247.9B (+37.8%), and Net Income attributable to owners of the parent was ¥152.7B (+51.3%). The Operating Income margin improved to 7.8% from 6.5% in the same period of the previous year, with a substantial improvement in the profitability of the Pharmaceuticals Business serving as the primary driver of consolidated earnings growth.

Factors Affecting Results

【Revenue】Revenue was ¥2,894.0B, up +5.8% YoY. By segment, Food was ¥2,339.4B (80.8% of total, +4.1% YoY), while Pharmaceuticals was ¥556.9B (19.2% of total, +13.6% YoY), indicating relatively stronger growth in the Pharmaceuticals Business.

【Profit and Loss】The cost of sales ratio was 69.3%, remaining broadly in line with the previous year, and securing a gross margin of 30.7%. Although the SG&A expense ratio increased slightly to 22.9%, the expansion in gross profit absorbed the increase, resulting in Operating Income of ¥226.7B (+27.7% YoY). By segment, Food recorded segment profit of ¥151.7B (+10.9% YoY, 6.5% margin), while Pharmaceuticals recorded ¥84.4B (+76.3% YoY, 15.2% margin). The sharp increase in the Pharmaceuticals margin was the primary factor behind the improvement in the consolidated margin. Ordinary Income of ¥247.9B benefited not only from Operating Income but also from improved non-operating income, including foreign exchange gains of ¥7.5B and dividend income of ¥6.2B. Extraordinary income of ¥13.7B (including gains on the sale of fixed assets of ¥6.4B) and extraordinary losses of ¥21.3B (including impairment losses of ¥11.0B) resulted in a net extraordinary loss of ¥7.6B, which weighed on Net Income; however, this did not materially impair the conversion from Pretax Income of ¥240.3B to Net Income of ¥152.7B. Revenue and earnings increased.

Segment Analysis

The Food Business recorded Revenue of ¥2,339.4B (+4.1% YoY) and segment profit of ¥151.7B (+10.9% YoY), with a 6.5% margin, accounting for 64.3% of consolidated segment profit as the core business. The Pharmaceuticals Business recorded Revenue of ¥556.9B (+13.6% YoY) and segment profit of ¥84.4B (+76.3% YoY), with a 15.2% margin, a substantial increase from 9.8% in the same period of the previous year. Although Food is overwhelmingly larger in terms of revenue, Pharmaceuticals surpassed Food in both profit growth and margin, meaning that the consolidated earnings increase was heavily dependent on improved profitability in this business. Corporate expenses (adjustments) were negative ¥9.3B, increasing from negative ¥7.2B in the previous year.

Key Financial Indicators

【Profitability】The Operating Income margin was 7.8%, improving from 6.5% in the same period of the previous year, while the Net Income margin was 5.3%, improving from 3.7%. ROE remained low at 2.0%, attributable to the low total asset turnover ratio on a Q1 cumulative basis.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥147.2B, maintaining an almost equivalent level at 0.96x Net Income, while OCF as a percentage of EBITDA of ¥352.9B remained at 0.42x, as increases in inventory and accounts receivable constrained cash conversion.【Investment Efficiency】Capital expenditures of ¥148.2B exceeded depreciation and amortization of ¥126.2B, indicating a front-loaded investment stance.【Financial Soundness】The Equity Ratio remained high at 63.6%, while current assets of ¥5,968.2B substantially exceeded current liabilities of ¥3,371.2B. Cash and deposits of ¥863.5B exceeded long-term borrowings of ¥670.9B, indicating a conservative financial position.

Cash Flow Analysis

OCF was ¥147.2B, improving from a substantial negative figure in the same period of the previous year. However, the increase in inventories of ¥199.6B and the increase in accounts receivable of ¥84.4B absorbed funds, resulting in a significant gap from the OCF subtotal before changes in working capital of ¥234.2B. Investing Cash Flow was negative ¥37.7B, with capital expenditures of ¥148.2B representing the primary outflow, partly offset by proceeds from subsidies and other items. Financing Cash Flow was positive ¥105.6B, with a net increase in short-term borrowings covering part of the funding for investment and shareholder returns. As a result, Free Cash Flow was positive at ¥109.5B; however, directly deducting capital expenditures from OCF would result in a small negative figure, making the reduction of inventories and accounts receivable key to improving future cash-generation capacity.

Quality of Earnings

Recurring earnings were supported by the increase in Operating Income and improvement in non-operating income. Although foreign exchange gains of ¥7.5B and dividend income of ¥6.2B cannot be considered entirely recurring because they include market-related factors, they are not sudden one-off items. Extraordinary income of ¥13.7B (including gains on the sale of fixed assets of ¥6.4B) and extraordinary losses of ¥21.3B (including impairment losses of ¥11.0B) should be distinguished as temporary factors, with the resulting net loss of ¥7.6B depressing Net Income. The OCF-to-Net Income ratio was 0.96x, with no significant divergence from an accrual perspective; however, working capital factors, namely increases in inventories and accounts receivable, created a temporary gap between accounting earnings and cash generation.

Earnings Forecast and Guidance

The Q1 progress rates against the full-year forecasts (Revenue of ¥1,212.0B, Operating Income of ¥100.0B, and Ordinary Income of ¥101.0B) were 23.9% for Revenue, 22.7% for Operating Income, and 24.5% for Ordinary Income, all around the standard level of approximately 25%. There were no revisions to either the earnings forecast or dividend forecast during the quarter, and the company’s plan remains unchanged. Although the Operating Income progress rate was 2.3pt below the standard level, the deviation was small and did not indicate at this point that the full-year plan was likely to be missed.

Shareholder Returns

The full-year dividend forecast is ¥110.00 per share, representing a planned increase from the previous year’s dividend of ¥52.5 (the annual level after combining the interim and year-end dividends). The forecast Payout Ratio, calculated using forecast full-year Net Income of ¥625.0B and the average number of shares outstanding during the period, is approximately 47.7%, remaining below 60%. Q1 dividend payments of ¥140.4B exceeded Free Cash Flow after deduction of Investing Cash Flow of ¥109.5B; however, the company’s financial capacity, including cash and deposits of ¥863.5B and an Equity Ratio of 63.6%, provides the background for this. Dividend sustainability should not be judged solely on the cash balance for a single quarter.

Risk Factors

1. Working capital cash absorption: Inventories increased by ¥199.6B and accounts receivable increased by ¥84.4B, respectively, while OCF growth failed to keep pace with Operating Income growth. If the structure in which revenue expansion does not readily translate into cash generation continues, it could affect the ability to finance investments and dividends with internally generated funds.

2. Dependence on disparities in segment margins: Much of the improvement in the consolidated Operating Income margin (+approximately 1.3pt YoY) depended on the increase in the Pharmaceuticals margin (from 9.8% to 15.2%), while the improvement in the Food Business alone was limited to approximately +0.4pt. The sustainability of the Pharmaceuticals Business’s high profitability will affect the stability of consolidated results.

3. Recognition of extraordinary losses (impairment losses): During the current period, the company recorded extraordinary losses of ¥21.3B, including impairment losses of ¥11.0B. Although the segment notes state that there were no significant impairments of fixed assets or significant changes in goodwill, this remains an item requiring continuous monitoring in terms of asset profitability.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (food_beverage)

Profitability and Returns

Both the Operating Income margin and Net Income margin exceeded the industry median, indicating that profitability was relatively high within the industry.

Growth and Capital Efficiency

The Revenue growth rate was slightly above the industry median; however, compared with the IQR upper bound of 10.1%, the growth rate was not exceptional within the industry.

※Source: Compiled by the company

Key Earnings Highlights

1. Revenue increased +5.8%, while Operating Income increased +27.7% and Net Income increased +51.3%, with earnings growth significantly exceeding revenue growth and confirming the emergence of operating leverage. The sustainability of this earnings momentum will depend on the Pharmaceuticals Business maintaining its high margin and the Food Business’s ability to pass through costs.

2. The Operating Income margin of 7.8% and Net Income margin of 5.6% exceeded the industry medians, while the OCF/EBITDA ratio remained at 0.42x, with increases in inventories and accounts receivable constraining cash generation. There was a divergence between earnings growth on the income statement and actual cash generation, making improved working capital efficiency a key focus going forward.

3. Progress rates against the full-year plan for all four major indicators were within the standard range of 22–25%, and both the company plan and dividend forecast remained unchanged. Pharmaceuticals segment profit had expanded to account for 35.7% of total segment profit, indicating that changes in the business portfolio mix are beginning to affect the medium-term earnings structure.

Theoretical Share Price (Reference Value)

Sensitivity: 2,588円〜2,737円 for a ±1% change in the Cost of Equity, and 2,654円〜2,665円 for a ±0.1 change in ω.

Notes:

• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).

（Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices）

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmark is reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Meiji Holdings delivered a strong FY2027 Q1 result, with profit growth materially outpacing sales growth and both operating segments contributing. Revenue increased 5.8% year on year to JPY 289.4bn. Operating income rose 27.7% to JPY 22.7bn, lifting the operating margin to 7.8% from 6.5% a year earlier, a 134bp expansion. Gross profit increased 11.1% to JPY 88.9bn and the gross margin expanded by 147bp to 30.7%, indicating that pricing, product mix and/or input-cost management more than offset inflationary pressures. SG&A increased 6.4% to JPY 66.2bn, slightly faster than sales, but much more slowly than gross profit. Consequently, the SG&A-to-sales ratio increased only 12bp to 22.9%, while operating leverage remained strongly positive. Ordinary income grew 37.8% to JPY 24.8bn, benefiting from higher operating income and a JPY 3.0bn non-operating income balance. Profit attributable to owners of parent increased 51.3% to JPY 15.3bn, with net margin improving by approximately 157bp to 5.3%. The Pharmaceutical segment was the principal incremental earnings driver, posting 76.3% segment-profit growth, while the Food segment provided the larger revenue and absolute profit base. Earnings conversion to operating cash flow was broadly acceptable on a net-income basis, with OCF of JPY 14.7bn equal to 0.96x profit attributable to owners. However, OCF-to-EBITDA cash conversion was only 0.42x, reflecting substantial working-capital absorption, especially inventory and receivables. Inventories increased by JPY 20.0bn in the quarter and trade receivables increased by JPY 8.4bn, only partly offset by a JPY 4.6bn increase in trade payables. Free cash flow was positive at JPY 10.9bn under the reported metric, despite JPY 14.8bn of capital expenditure. The balance sheet remains conservatively capitalized, with a 177.0% current ratio, 128.9% quick ratio, 0.57x debt-to-equity ratio and 65.5x EBIT interest coverage. Nevertheless, short-term loans nearly doubled year on year to JPY 41.2bn, and this funding movement should be monitored alongside elevated inventory-related working-capital needs. Q1 operating-income progress reached 22.7% of the full-year forecast, modestly below the standard 25% quarterly run rate but not sufficiently divergent to imply a material forecast shortfall. The company maintained both its earnings forecast and dividend plan, and the forecast DPS of JPY 110 implies a moderate 47.7% dividend payout ratio against forecast EPS of JPY 230.61. The central issue for subsequent quarters is whether improved gross-margin performance can be retained while inventory, receivable and cash-conversion pressures normalize.

Profitability Analysis

Annualized reported ROE is 7.5%, below the 8% threshold generally associated with a stronger return profile, but it improved operationally in Q1 through margin expansion rather than a more aggressive capital structure. The reported three-factor DuPont decomposition is net profit margin of 5.3%, asset turnover of 0.900x and financial leverage of 1.57x. Financial leverage is restrained, meaning the return profile is predominantly determined by operating profitability and asset efficiency rather than balance-sheet gearing. The largest favorable Q1 movement was margin expansion: operating margin increased 134bp year on year to 7.8%, while gross margin rose 147bp to 30.7%. This indicates that the increase in gross profit of JPY 8.9bn exceeded the JPY 4.0bn increase in SG&A, producing substantial operating leverage. SG&A grew 6.4%, modestly above the 5.8% revenue increase, so cost discipline remains an item to monitor; however, the rate was far below the 11.1% gross-profit growth. The five-factor DuPont profile shows a 0.635 tax burden and a 1.060 interest burden. The interest burden above 1.0 reflects net non-operating income rather than debt pressure, supported by very low interest expense of JPY 0.3bn versus JPY 22.7bn EBIT. The effective tax rate was 32.4%, and therefore tax remains a meaningful constraint on conversion of pre-tax profit into net profit. Net income was also affected by a net extraordinary loss of JPY 0.8bn, comprising JPY 1.4bn of extraordinary income and JPY 2.1bn of extraordinary loss. The extraordinary loss included JPY 1.1bn of impairment loss, which reduced reported profit but is non-recurring in nature. EBITDA was JPY 35.3bn and the EBITDA margin was 12.2%, providing a stronger view of operating cash earnings than the 7.8% EBIT margin. Capex was 1.17x depreciation and amortization, indicating continued reinvestment above the depreciation run rate. As a JGAAP reporter, Meiji would amortize any recognized goodwill, but the provided EBITDA before goodwill amortization equals reported EBITDA, indicating no separately identified goodwill-amortization adjustment in the available figures.

Growth Assessment

Revenue growth of 5.8% was supported by both operating segments. Food, the core business by its JPY 233.7bn external revenue and JPY 15.2bn segment profit, increased sales by 4.1% year on year and segment profit by 10.9%. Food segment margin improved 41bp to 6.5%, demonstrating moderate but constructive earnings leverage in the company’s largest business. Pharmaceutical sales increased 13.6% to JPY 55.7bn and segment profit rose 76.3% to JPY 8.4bn. Pharmaceutical segment margin expanded sharply by 538bp to 15.2% from 9.8%, making it the primary source of group margin improvement. The mix shift toward the higher-margin Pharmaceutical business is favorable for group profitability, although the durability of its exceptional Q1 profit growth is central to the outlook. Group sales growth exceeded the full-year revenue-growth assumption of 3.3%, while Q1 operating-income growth of 27.7% significantly exceeded the full-year operating-income growth assumption of 7.2%. Against the full-year forecast, Q1 revenue progress was 23.9%, 1.1 percentage points below the standard 25% run rate. Operating-income progress was 22.7%, 2.3 percentage points below the standard run rate, while ordinary-income progress was 24.5% and profit attributable to owners progress was 24.4%. These progress rates are modestly below a simple linear seasonal benchmark but remain broadly consistent with the maintained full-year forecast. No forecast revision was announced. For a food and beverage manufacturer, the 30.7% gross margin is within the healthy 25-40% industry range and represents an improved starting point for the year. The key sustainability tests are the persistence of food pricing and mix benefits, the normalization of inventory investment, commodity and foreign-exchange conditions, and whether Pharmaceutical profitability remains at an elevated level.

Financial Health

Liquidity is strong. Current assets of JPY 596.8bn exceeded current liabilities of JPY 337.1bn, producing working capital of JPY 259.7bn and a current ratio of 177.0%. The 128.9% quick ratio shows that short-term liquidity remains adequate even excluding inventory. Cash and deposits were JPY 86.3bn, equivalent to 2.10x short-term debt under the reported covenant metric. Interest-bearing debt was JPY 108.3bn, comprising JPY 41.2bn of short-term loans and JPY 67.1bn of long-term loans. The 38.0% short-term debt ratio does not indicate a severe maturity mismatch because current assets are substantial and liquid resources exceed short-term debt. Solvency is also sound, with a reported debt-to-equity ratio of 0.57x, debt-to-capital of 11.7%, and interest coverage of 65.5x on EBIT and 102.0x on EBITDA. Debt/EBITDA of 3.07x is below the 4.0x high-yield warning threshold but above the 2.5x investment-grade reference point, warranting monitoring despite strong coverage ratios. The material balance-sheet movement is short-term loans, which increased JPY 19.9bn, or 93.2% year on year, to JPY 41.2bn. This rise broadly aligns with quarterly financing cash inflow of JPY 10.6bn, including a JPY 20.0bn net increase in short-term loans and a JPY 10.0bn bond redemption. Accordingly, the higher short-term borrowing appears associated with liability refinancing and funding requirements rather than a deterioration in long-term solvency. Total equity was essentially unchanged year on year at JPY 817.5bn, while owners’ equity was JPY 772.3bn. Net defined-benefit liability of JPY 41.6bn is a relevant long-duration obligation, but it is modest relative to total equity. The balance sheet has meaningful operating-asset intensity, with PPE representing 40.7% of total assets, reinforcing the importance of maintaining adequate operating cash flow and disciplined capital expenditure.

Notable B/S Changes

Short-term loans: +JPY 19.9bn (+93.2%) to JPY 41.2bn - a material increase in short-term funding, partly associated with quarterly financing activity and a JPY 10.0bn bond redemption; monitor refinancing reliance and working-capital funding needs. Inventories: +JPY 17.7bn (+12.2%) to JPY 162.4bn - the percentage increase is below 20%, but the absolute increase exceeds JPY 5.0bn and is consistent with the elevated inventory-day and cash-conversion-cycle alerts; monitor demand alignment, commodity exposure and cash release. Property, plant and equipment: +JPY 14.0bn (+2.7%) to JPY 523.9bn - continued asset investment is supported by capital expenditure of JPY 14.8bn, reinforcing the need for adequate utilization and operating-cash-flow conversion.

Cash Flow Quality

Operating cash flow was JPY 14.7bn, equivalent to 0.96x profit attributable to owners of JPY 15.3bn. This is below the 1.0x high-quality benchmark but above the 0.8x level that would indicate a more pronounced earnings-quality concern. The reported accruals ratio of 0.0% is favorable and does not signal elevated accounting accrual risk. Nevertheless, the quality alert for low cash conversion must be addressed: OCF/EBITDA was only 0.42x, below the 0.7x warning benchmark. The root cause is working-capital absorption, including a JPY 20.0bn inventory increase and a JPY 8.4bn receivable increase, which more than offset supportive increases in trade payables. This level of conversion is not desirable for a mature food and pharmaceutical group because it constrains internally generated cash available for investment and distributions. Its impact is a greater dependence on cash balances and short-term funding if the working-capital build persists beyond seasonal needs. The first high-inventory-days alert identifies DIO of 126 days, above the 90-day warning threshold. Its root cause is the sizable inventory position relative to quarterly cost of sales and the quarter’s inventory accumulation. The second high-inventory-days alert identifies 74 days, above the processed-food benchmark of 60 days. Its root cause is likewise inventory intensity, and it remains concerning even under the less severe measure because food inventories can be exposed to spoilage, demand shifts and raw-material price movements. Both inventory alerts point to the same investment implication: inventory normalization is needed to improve cash conversion and reduce obsolescence and commodity-exposure risk. The long-CCC alert of 137 days, above the 120-day warning threshold, is driven by the combination of high inventory days and receivable funding requirements. A 137-day cash conversion cycle is well above the food-industry benchmark of below 60 days and indicates material capital tied up in operations. Investing cash flow was negative JPY 3.8bn, while capital expenditure was JPY 14.8bn and was partly offset by JPY 7.5bn of subsidies received. Reported free cash flow was positive JPY 10.9bn, but its sustainability depends on improved working-capital conversion because operating cash flow did not fully cover the quarter’s JPY 14.8bn capital expenditure on a direct OCF-less-capex basis. Financing cash flow was positive JPY 10.6bn, while cash dividends paid were JPY 14.0bn, demonstrating that quarterly cash movements were supported by financing as well as operating inflow.

Dividend Sustainability

The full-year planned dividend of JPY 110 per share implies a dividend payout ratio of 47.7% against forecast EPS of JPY 230.61. This is below the 60% sustainability benchmark and leaves a reasonable earnings retention buffer. Q1 EPS was JPY 56.33, representing 24.4% of full-year forecast EPS, broadly aligned with the quarterly profit-progress rate. Cash dividends paid during Q1 were JPY 14.0bn. Reported free cash flow of JPY 10.9bn was positive but did not fully cover the quarter’s cash dividend payment, implying that distribution funding was not entirely supported by reported free cash flow in the period. This does not by itself undermine dividend capacity given cash deposits of JPY 86.3bn, strong liquidity ratios and low debt-to-capital of 11.7%. However, the low 0.42x OCF/EBITDA conversion and long 137-day cash conversion cycle are the principal constraints on cash dividend coverage quality. Capital expenditure of 1.17x depreciation also indicates that management is maintaining a growth and maintenance investment program, which competes with dividends for cash allocation. The maintained dividend plan and maintained earnings forecast support near-term policy continuity. Dividend sustainability would improve if inventory and receivables unwind in later quarters and operating cash flow rises closer to EBITDA and net-income generation. No share repurchases were material in the reported financing cash-flow data, so the assessment is based on the dividend payout ratio rather than a total return ratio.

Risk Assessment

Business risks include Food cost and commodity exposure: raw materials were JPY 104.5bn and inventory intensity is elevated, leaving profitability exposed to movements in dairy, cocoa, sugar, grains, packaging and energy costs. The Q1 gross-margin gain must be tested against future input-cost and pricing conditions., Food inventory and demand risk: the quality alerts identify inventory days of 126 days and 74 days, both above their respective warning benchmarks. Higher inventory increases the risk of obsolescence, product-mix misalignment and additional working-capital needs., Pharmaceutical earnings sustainability: Pharmaceutical segment profit increased 76.3% year on year and margin rose 538bp to 15.2%. This exceptional improvement is favorable, but group profit growth will moderate if the segment does not sustain this higher profitability level., Food safety, recall and regulatory risk: as a large food manufacturer, the company remains exposed to quality-control events, labeling and ingredient regulations, and reputational consequences from product recalls., Foreign-exchange risk: foreign-exchange gains were JPY 0.7bn in Q1, while imported ingredients and international operations can create earnings sensitivity to currency changes..

Financial risks include Low cash conversion: OCF/EBITDA of 0.42x is below the 0.7x quality threshold. The effect is reduced internally generated cash to fund capital expenditure and distributions., Long cash conversion cycle: the 137-day CCC is above the 120-day alert threshold and substantially above the food-industry benchmark, increasing capital tied up in working capital., Short-term borrowing increase: short-term loans rose 93.2% year on year to JPY 41.2bn. Liquidity remains strong, but continuation of short-term funding growth would increase refinancing sensitivity., Debt/EBITDA monitoring: reported debt/EBITDA of 3.07x is manageable but above the 2.5x investment-grade reference benchmark, notwithstanding very strong interest coverage..

Key concerns include The key near-term issue is conversion of improved accounting earnings into cash, particularly whether the JPY 20.0bn inventory increase and JPY 8.4bn receivable increase reverse as sales progress., The higher margin profile is driven disproportionately by Pharmaceutical segment profit acceleration; the durability and repeatability of this contribution are important for full-year forecast delivery., Impairment loss of JPY 1.1bn was recorded in Q1. Although not large relative to equity, it warrants monitoring as an indicator of asset-level return discipline in the capital-intensive manufacturing base., No major goodwill movement was reported, and intangible assets are only 1.7% of total assets, limiting M&A-related goodwill and intangible-asset concentration risk..

Investment Implications

Key takeaways include Q1 showed strong earnings momentum: revenue grew 5.8%, operating income grew 27.7%, and profit attributable to owners grew 51.3%., Operating margin expanded 134bp to 7.8%, led by a 147bp improvement in gross margin to 30.7%., Food remains the core business, while Pharmaceutical was the primary source of incremental earnings and margin expansion., The capital structure is conservative, supported by 177.0% current ratio, 0.57x debt-to-equity, 11.7% debt-to-capital and 65.5x EBIT interest coverage., Cash-flow conversion and inventory discipline are the principal counterweights to the strong income-statement performance., The JPY 110 forecast dividend appears earnings-covered, with a 47.7% forecast dividend payout ratio, but stronger free-cash-flow coverage requires working-capital improvement..

Metrics to watch include Food and Pharmaceutical segment revenue growth and segment margins, particularly the sustainability of Pharmaceutical’s 15.2% Q1 margin., Gross margin and the ability to preserve pricing and mix benefits amid commodity, packaging, logistics and currency volatility., OCF/EBITDA cash conversion, with improvement from the current 0.42x level as the central cash-quality indicator., Inventory balance and inventory days, including the alerts at 126 days and 74 days., Cash conversion cycle, currently alerted at 137 days., Trade receivable and inventory movements relative to sales growth., Short-term loans, which increased 93.2% year on year, and the degree to which financing cash flow remains necessary., Progress against full-year forecasts: Q1 revenue progress of 23.9%, operating-income progress of 22.7%, and profit attributable to owners progress of 24.4%..

Regarding relative positioning, Meiji’s Q1 gross margin of 30.7% lies within the healthy 25-40% food and beverage range, while its 7.8% operating margin is approaching the lower end of the 8-15% range considered good under the supplied benchmark. Its liquidity, leverage and interest-coverage profile are stronger than those of a highly geared consumer staples issuer. In contrast, its inventory-day and 137-day cash-conversion-cycle alerts indicate weaker working-capital efficiency than the food-industry benchmark, making cash conversion the principal area where financial execution lags the otherwise solid earnings and balance-sheet profile.